Effects of pioglitazone, a peroxisome proliferator-Activated receptor gamma agonist, on the urine and urothelium of the rat

Shugo Suzuki, Lora L Arnold, Karen L. Pennington, Satoko Kakiuchi-Kiyota, Min Wei, Hideki Wanibuchi, Samuel Monroe Cohen

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which belong to the nuclear receptor superfamily. Some PPARγ agonists, such as pioglitazone, and dual PPARγ/PPARα agonists, such as muraglitazar, induced urothelial bladder tumors in rats but not in mice. In this study, we investigated the early effects in the urine and bladder of rats treated with pioglitazone to evaluate the possible relation between urinary solids formation and urothelial cytotoxicity and regenerative proliferation. In a 4-week experiment, treatment of rats with 16 mg/kg pioglitazone induced cytotoxicity and necrosis of the urothelial superficial layer, with increased cell proliferation measured by bromodeoxyuridine labeling index and hyperplasia by histology. It also produced alterations in urinary solid formation, especially calcium-containing crystals and calculi. PPARγ agonists (pioglitazone and troglitazone) in vitro reduced rat urothelial cell proliferation and induced uroplakin synthesis, a specific differentiation marker in urothelial cells. Our data support the hypothesis that the bladder tumors produced in rats by pioglitazone are related to the formation of urinary solids. This strongly supports the previous conclusion in studies with muraglitazar that this is a rat-specific phenomenon and does not pose a urinary bladder cancer risk to humans treated with these agents.

Original languageEnglish (US)
Article numberkfp256
Pages (from-to)349-357
Number of pages9
JournalToxicological Sciences
Volume113
Issue number2
DOIs
StatePublished - Oct 25 2009

Fingerprint

pioglitazone
Urothelium
PPAR gamma
Peroxisome Proliferator-Activated Receptors
Rats
Urine
Urinary Bladder Neoplasms
Cell proliferation
troglitazone
Cytotoxicity
Tumors
Uroplakins
Cell Proliferation
Histology
Differentiation Antigens
Calculi
Bromodeoxyuridine
Cytoplasmic and Nuclear Receptors
Labeling
Hyperplasia

Keywords

  • Differentiation
  • Peroxisome proliferator-activated receptor
  • Urinary bladder
  • Urinary solids
  • Urothelial cell cytotoxicity

ASJC Scopus subject areas

  • Toxicology

Cite this

Effects of pioglitazone, a peroxisome proliferator-Activated receptor gamma agonist, on the urine and urothelium of the rat. / Suzuki, Shugo; Arnold, Lora L; Pennington, Karen L.; Kakiuchi-Kiyota, Satoko; Wei, Min; Wanibuchi, Hideki; Cohen, Samuel Monroe.

In: Toxicological Sciences, Vol. 113, No. 2, kfp256, 25.10.2009, p. 349-357.

Research output: Contribution to journalArticle

Suzuki, Shugo ; Arnold, Lora L ; Pennington, Karen L. ; Kakiuchi-Kiyota, Satoko ; Wei, Min ; Wanibuchi, Hideki ; Cohen, Samuel Monroe. / Effects of pioglitazone, a peroxisome proliferator-Activated receptor gamma agonist, on the urine and urothelium of the rat. In: Toxicological Sciences. 2009 ; Vol. 113, No. 2. pp. 349-357.
@article{ec1b88ce35984ffca148d148237dba01,
title = "Effects of pioglitazone, a peroxisome proliferator-Activated receptor gamma agonist, on the urine and urothelium of the rat",
abstract = "Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which belong to the nuclear receptor superfamily. Some PPARγ agonists, such as pioglitazone, and dual PPARγ/PPARα agonists, such as muraglitazar, induced urothelial bladder tumors in rats but not in mice. In this study, we investigated the early effects in the urine and bladder of rats treated with pioglitazone to evaluate the possible relation between urinary solids formation and urothelial cytotoxicity and regenerative proliferation. In a 4-week experiment, treatment of rats with 16 mg/kg pioglitazone induced cytotoxicity and necrosis of the urothelial superficial layer, with increased cell proliferation measured by bromodeoxyuridine labeling index and hyperplasia by histology. It also produced alterations in urinary solid formation, especially calcium-containing crystals and calculi. PPARγ agonists (pioglitazone and troglitazone) in vitro reduced rat urothelial cell proliferation and induced uroplakin synthesis, a specific differentiation marker in urothelial cells. Our data support the hypothesis that the bladder tumors produced in rats by pioglitazone are related to the formation of urinary solids. This strongly supports the previous conclusion in studies with muraglitazar that this is a rat-specific phenomenon and does not pose a urinary bladder cancer risk to humans treated with these agents.",
keywords = "Differentiation, Peroxisome proliferator-activated receptor, Urinary bladder, Urinary solids, Urothelial cell cytotoxicity",
author = "Shugo Suzuki and Arnold, {Lora L} and Pennington, {Karen L.} and Satoko Kakiuchi-Kiyota and Min Wei and Hideki Wanibuchi and Cohen, {Samuel Monroe}",
year = "2009",
month = "10",
day = "25",
doi = "10.1093/toxsci/kfp256",
language = "English (US)",
volume = "113",
pages = "349--357",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Effects of pioglitazone, a peroxisome proliferator-Activated receptor gamma agonist, on the urine and urothelium of the rat

AU - Suzuki, Shugo

AU - Arnold, Lora L

AU - Pennington, Karen L.

AU - Kakiuchi-Kiyota, Satoko

AU - Wei, Min

AU - Wanibuchi, Hideki

AU - Cohen, Samuel Monroe

PY - 2009/10/25

Y1 - 2009/10/25

N2 - Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which belong to the nuclear receptor superfamily. Some PPARγ agonists, such as pioglitazone, and dual PPARγ/PPARα agonists, such as muraglitazar, induced urothelial bladder tumors in rats but not in mice. In this study, we investigated the early effects in the urine and bladder of rats treated with pioglitazone to evaluate the possible relation between urinary solids formation and urothelial cytotoxicity and regenerative proliferation. In a 4-week experiment, treatment of rats with 16 mg/kg pioglitazone induced cytotoxicity and necrosis of the urothelial superficial layer, with increased cell proliferation measured by bromodeoxyuridine labeling index and hyperplasia by histology. It also produced alterations in urinary solid formation, especially calcium-containing crystals and calculi. PPARγ agonists (pioglitazone and troglitazone) in vitro reduced rat urothelial cell proliferation and induced uroplakin synthesis, a specific differentiation marker in urothelial cells. Our data support the hypothesis that the bladder tumors produced in rats by pioglitazone are related to the formation of urinary solids. This strongly supports the previous conclusion in studies with muraglitazar that this is a rat-specific phenomenon and does not pose a urinary bladder cancer risk to humans treated with these agents.

AB - Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which belong to the nuclear receptor superfamily. Some PPARγ agonists, such as pioglitazone, and dual PPARγ/PPARα agonists, such as muraglitazar, induced urothelial bladder tumors in rats but not in mice. In this study, we investigated the early effects in the urine and bladder of rats treated with pioglitazone to evaluate the possible relation between urinary solids formation and urothelial cytotoxicity and regenerative proliferation. In a 4-week experiment, treatment of rats with 16 mg/kg pioglitazone induced cytotoxicity and necrosis of the urothelial superficial layer, with increased cell proliferation measured by bromodeoxyuridine labeling index and hyperplasia by histology. It also produced alterations in urinary solid formation, especially calcium-containing crystals and calculi. PPARγ agonists (pioglitazone and troglitazone) in vitro reduced rat urothelial cell proliferation and induced uroplakin synthesis, a specific differentiation marker in urothelial cells. Our data support the hypothesis that the bladder tumors produced in rats by pioglitazone are related to the formation of urinary solids. This strongly supports the previous conclusion in studies with muraglitazar that this is a rat-specific phenomenon and does not pose a urinary bladder cancer risk to humans treated with these agents.

KW - Differentiation

KW - Peroxisome proliferator-activated receptor

KW - Urinary bladder

KW - Urinary solids

KW - Urothelial cell cytotoxicity

UR - http://www.scopus.com/inward/record.url?scp=75249084816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75249084816&partnerID=8YFLogxK

U2 - 10.1093/toxsci/kfp256

DO - 10.1093/toxsci/kfp256

M3 - Article

C2 - 19858066

AN - SCOPUS:75249084816

VL - 113

SP - 349

EP - 357

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 2

M1 - kfp256

ER -